Nearly 375,000 bottles of antidepressant recalled over cancer-linked impurity

Nearly 375,000 bottles of antidepressant medication are being recalled following the discovery of a cancer-linked impurity. This significant recall emphasizes the critical importance of stringent quality control measures and contaminant testing within the pharmaceutical manufacturing process. For industry stakeholders, the event serves as a reminder of the potential for large-scale disruptions and the regulatory scrutiny surrounding chemical impurities in widely used medications. The scale of the recall highlights the ongoing challenges manufacturers face in ensuring product purity across high-volume distribution channels.